Enthesis healing
US-2024390292-A1 · Nov 28, 2024 · US
US12296127B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12296127-B2 |
| Application number | US-202318125810-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 24, 2023 |
| Priority date | Dec 11, 2007 |
| Publication date | May 13, 2025 |
| Grant date | May 13, 2025 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
An implantable medical device is provided for controlled drug delivery within the bladder, or other body vesicle. The device may include at least one drug reservoir component comprising a drug; and a vesicle retention frame which comprises an elastic wire having a first end, an opposing second end, and an intermediate region therebetween, wherein the drug reservoir component is attached to the intermediate region of the vesicle retention frame. The retention frame prevents accidental voiding of the device from the bladder, and it preferably has a spring constant selected for the device to effectively stay in the bladder during urination while minimizing the irritation of the bladder.
Opening claim text (preview).
We claim: 1. An intravesical drug delivery device comprising: a tubular body housing a drug, wherein the tubular body is formed in a configuration having a sufficient spring constant to retain the device in a patient's bladder, and wherein the tubular body has a shape which has exactly two smaller arches sharing a single common larger arch. 2. The device of claim 1 , wherein the spring constant is from 3 N/m to 60 N/m. 3. The device of claim 1 , wherein the spring constant is from 3.6 N/m to 3.8 N/m. 4. The device of claim 1 , wherein the tubular body comprises silicone. 5. The device of claim 1 , wherein the drug is part of a solid drug formulation. 6. The device of claim 1 , wherein the tubular body comprises an aperture configured to release the drug therethrough. 7. The device of claim 1 , wherein the tubular body has no aperture and is configured to release the drug by diffusion through a wall in the tubular body. 8. The device of claim 1 , wherein ends of the tubular body are sealed to prevent escape of the drug from the ends. 9. The device of claim 1 , wherein the tubular body comprises a non-resorbable, water permeable material. 10. The device of claim 1 , wherein the tubular body comprises a polyurethane. 11. The device of claim 1 , wherein the drug comprises an antiproliferative agent, a cytotoxic agent, or a chemotherapeutic agent. 12. An intravesical drug delivery device comprising: a drug reservoir portion which contains a drug and controls in vivo release of the drug into a patient's bladder; and a retention frame portion configured to impede voiding of the intravesical drug delivery device from the patient's bladder, wherein the drug reservoir portion and the retention frame portion are the same component of the intravesical drug delivery device, wherein the same component comprises a tubular body having a shape which has exactly two smaller arches sharing a single common larger arch. 13. The device of claim 12 , wherein the tubular body is formed in a configuration having a spring constant from 3 N/m to 60 N/m. 14. The device of claim 12 , wherein the tubular body is formed in a configuration having a spring constant from 3.6 N/m to 3.8 N/m. 15. The device of claim 12 , wherein the tubular body comprises an aperture configured to release the drug therethrough. 16. The device of claim 12 , wherein the tubular body has no aperture and is configured to release the drug by diffusion through a wall in the tubular body. 17. The device of claim 12 , wherein the drug is part of a solid drug formulation. 18. The device of claim 12 , wherein ends of the tubular body are sealed to prevent escape of the drug from the ends. 19. The device of claim 12 , wherein the tubular body comprises a non-resorbable, water permeable material. 20. The device of claim 12 , wherein the tubular body comprises a polyurethane. 21. The device of claim 12 , wherein the drug comprises an antiproliferative agent, a cytotoxic agent, or a chemotherapeutic agent.
Bladder · CPC title
Materials providing elastic properties, e.g. for facilitating deformation and avoid breaking · CPC title
using radio-opaque or ultrasound markers · CPC title
Insertion or introduction using an inner stiffening member, e.g. stylet or push-rod · CPC title
having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.